- Rekrutierung läuftA Phase 3 Trial of Epcoritamab vs Investigator´s Choice Chemotherapy in R/R DLBCL
- Rekrutierung läuft
AN OPEN-LABEL, MULTICENTER, PHASE I/IB TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
Molekulare Marker - Rekrutierung läuftA RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE-POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION
- Rekrutierung läuft
A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Molekulare Marker - Rekrutierung läuft
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphom
Molekulare Marker - Rekrutierung läuft
This is an open-label, multi-center, Phase I study to investigate the safety and tolerability of REGN1979, an Anti-CD20 X Anti CD3 Bispecific Monoclonal Antibody, in patients with CD20+ B-Cell Malignancies previously treated with CD20- Directed Antibody Therapy
Molekulare Marker - Rekrutierung läuftA Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a
Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory
Multiple Myeloma